These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 18801601)

  • 21. Eculizumab opens a new era of treatment for paroxysmal nocturnal hemoglobinuria.
    Schrezenmeier H; Höchsmann B
    Expert Rev Hematol; 2009 Feb; 2(1):7-16. PubMed ID: 21082989
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Eculizumab in paroxysmal nocturnal hemoglobinuria.
    Kathula SK
    N Engl J Med; 2006 Dec; 355(26):2786; author reply 2787-8. PubMed ID: 17192547
    [No Abstract]   [Full Text] [Related]  

  • 23. [Evidence of the efficacy of eculizumab in paroxysmal nocturnal hemoglobinuria].
    Nau JY
    Rev Med Suisse; 2006 Oct; 2(81):2255. PubMed ID: 17076159
    [No Abstract]   [Full Text] [Related]  

  • 24. Eculizumab in paroxysmal nocturnal hemoglobinuria.
    Pride YB
    N Engl J Med; 2006 Dec; 355(26):2787; author reply 2787-8. PubMed ID: 17195305
    [No Abstract]   [Full Text] [Related]  

  • 25. [Pathophysiology and treatment of paroxysmal nocturnal hemoglobinuria (PNH)--recent advances].
    Shichishima A; Shichishima T;
    Rinsho Ketsueki; 2009 Dec; 50(12):1679-86. PubMed ID: 20068274
    [No Abstract]   [Full Text] [Related]  

  • 26. [Eculizumab in paroxysmal nocturnal hemoglobinuria].
    Birgens H
    Ugeskr Laeger; 2011 Mar; 173(10):714. PubMed ID: 21375975
    [No Abstract]   [Full Text] [Related]  

  • 27. Photodermatosis associated with eculizumab (Soliris): a novel monoclonal antibody directed against the complement protein C5.
    Balagula Y; Newman SB; Lacouture ME
    Am J Hematol; 2010 May; 85(5):392-3. PubMed ID: 20232400
    [No Abstract]   [Full Text] [Related]  

  • 28. Thrombosis in patients with paroxysmal nocturnal hemoglobinuria.
    Weitz IC
    Semin Thromb Hemost; 2011 Apr; 37(3):315-21. PubMed ID: 21455865
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adverse reactions and medical approach to paroxysmal nocturnal hemoglobinuria.
    Colombo GM; Guglielmelli E; Sacco T; Cicchinelli M
    Minerva Med; 2007 Feb; 98(1):87-8. PubMed ID: 17372586
    [No Abstract]   [Full Text] [Related]  

  • 30. Assessment of human antihuman antibodies to eculizumab after long-term treatment in patients with paroxysmal nocturnal hemoglobinuria.
    Hillmen P; Muus P; Szer J; Hill A; Höchsmann B; Kulasekararaj A; Risitano AM; Van Den Neste E; Liljeholm M; Ebrahim KS; Bedrosian CL; Gao X; Ames D; Socié G
    Am J Hematol; 2016 Mar; 91(3):E16-7. PubMed ID: 26690023
    [No Abstract]   [Full Text] [Related]  

  • 31. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria.
    Rother RP; Rollins SA; Mojcik CF; Brodsky RA; Bell L
    Nat Biotechnol; 2007 Nov; 25(11):1256-64. PubMed ID: 17989688
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Eculizumab in paroxysmal nocturnal hemoglobinuria.
    Singh J; Malani AK; Pabla M
    N Engl J Med; 2006 Dec; 355(26):2786; author reply 2787-8. PubMed ID: 17195307
    [No Abstract]   [Full Text] [Related]  

  • 33. Hereditary Hemochromatosis Manifesting After Treatment of Paroxysmal Nocturnal Hemoglobinuria With Eculizumab.
    Elliott E; Waheed S; Syed S; Eswaran S; Gregory S; Shammo J
    Clin Lymphoma Myeloma Leuk; 2018 Jan; 18(1):e9-e12. PubMed ID: 29102415
    [No Abstract]   [Full Text] [Related]  

  • 34. Disseminated gonococcal infection in a patient with paroxysmal nocturnal haemoglobinuria receiving eculizumab.
    Niitsuma-Sugaya I; Kanamori H; Ichikawa S; Fukuhara N; Seike I; Takei K; Baba H; Oshima K; Aoyagi T; Harigae H; Tokuda K
    Lancet Infect Dis; 2021 May; 21(5):741. PubMed ID: 33894850
    [No Abstract]   [Full Text] [Related]  

  • 35. Cardiopulmonary bypass in a patient with classic paroxysmal nocturnal hemoglobinuria during treatment with eculizumab.
    van Bijnen ST; Vermeer H; Mourisse JM; de Witte T; van Swieten HA; Muus P
    Eur J Haematol; 2011 Oct; 87(4):376-8. PubMed ID: 21623921
    [No Abstract]   [Full Text] [Related]  

  • 36. The complement C5 inhibitor crovalimab in paroxysmal nocturnal hemoglobinuria.
    Röth A; Nishimura JI; Nagy Z; Gaàl-Weisinger J; Panse J; Yoon SS; Egyed M; Ichikawa S; Ito Y; Kim JS; Ninomiya H; Schrezenmeier H; Sica S; Usuki K; Sicre de Fontbrune F; Soret J; Sostelly A; Higginson J; Dieckmann A; Gentile B; Anzures-Cabrera J; Shinomiya K; Jordan G; Biedzka-Sarek M; Klughammer B; Jahreis A; Bucher C; Peffault de Latour R
    Blood; 2020 Mar; 135(12):912-920. PubMed ID: 31978221
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Progress in the management of paroxysmal nocturnal hemoglobinuria by eculizumab].
    Nakakuma H
    Rinsho Ketsueki; 2011 Aug; 52(8):633-44. PubMed ID: 21897069
    [No Abstract]   [Full Text] [Related]  

  • 38. Eculizumab (Soliris) for paroxysmal nocturnal hemoglobinuria.
    Med Lett Drugs Ther; 2007 Sep; 49(1270):79-80. PubMed ID: 17878890
    [No Abstract]   [Full Text] [Related]  

  • 39. Update in paroxysmal nocturnal hemoglobinuria.
    Hillmen P
    Clin Adv Hematol Oncol; 2012 Jun; 10(6):391-3. PubMed ID: 22895241
    [No Abstract]   [Full Text] [Related]  

  • 40. Durable resolution of recurrent microvascular small bowel ischaemia and severe abdominal pain by eculizumab in paroxysmal nocturnal haemoglobinuria.
    Grigg A; Brown M; Szer J
    Intern Med J; 2010 Nov; 40(11):794-5. PubMed ID: 21108715
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.